gdc
Lung Cancer

Minimally Invasive Surgery May Offer Benefits for Patients with Lung Cancer

“Almost anyone who is a candidate for lung surgery is generally a candidate for minimally invasive surgery,” says Richard Chang, MD, FACS. Newer types of surgery are becoming available for patients with lung cancer that has not spread to other organs.
November 2018 Volume 4 – Lung Cancer
Kristen Chanley

Surgery provides the best chance to cure early-stage lung cancer and plays an important role for patients who have been diagnosed with early-stage non–small-cell lung cancer (NSCLC), the most common type of lung cancer. Newer types of surgery are becoming available for patients with lung cancer that has not spread to other organs, allowing patients to have surgery with less pain and with a quicker recovery period.

Share this:

Recommended For You
Patient StoriesLung Cancer
A Walking Miracle: My Cancer Journey
By Veronica Brent
When Veronica Brent had a constant cough and shortness of breath from walking, her daughter suggested she should have a chest x-ray. The x-ray showed she had lung cancer, and a biopsy showed she had cancer on the pancreas. She was concerned how to break the news to the family.
FDA Approvals, News & UpdatesLung Cancer
FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the first MET inhibitor that has been approved by the FDA.
FDA Approvals, News & UpdatesLung Cancer
Tagrisso Approved as Adjuvant Therapy for Patients with Lung Cancer and EGFR Mutations
In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer.
FDA Approvals, News & UpdatesLung Cancer
Immunotherapy Combination Provides New Hope for Patients with Certain Type of Non–Small-Cell Lung Cancer
A treatment combination containing the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) received 2 approvals in non–small-cell lung cancer (NSCLC) in the past year.
Last modified: June 22, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country